Publications by authors named "B Ferwerda"
Background: High heritability of salt sensitivity suggests an essential role for genetics in the relationship between sodium intake and blood pressure (BP). The role of glycosaminoglycan genes, which are crucial for salinity tolerance, remains to be elucidated.
Methods: Interactions between 54 126 variants in 130 glycosaminoglycan genes and daily sodium excretion on BP were explored in 20 420 EPIC-Norfolk (European Prospective Investigation Into Cancer in Norfolk) subjects.
Background: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2.
Objectives: Our goal was to investigate the effects of genetic variants on risk and time to LID.
Aims/hypothesis: Use of genetic risk scores (GRS) may help to distinguish between type 1 diabetes and type 2 diabetes, but less is known about whether GRS are associated with disease severity or progression after diagnosis. Therefore, we tested whether GRS are associated with residual beta cell function and glycaemic control in individuals with type 1 diabetes.
Methods: Immunochip arrays and TOPMed were used to genotype a cross-sectional cohort (n=479, age 41.
Article Synopsis
- Gut microbiota may influence blood lipid levels and cardiovascular disease (CVD) risk, with differences observed among various ethnic groups.
- A study involving 3,860 participants without CVD history showed that specific gut microbes were linked to CVD phenotypes, often varying by ethnicity, using machine learning and Mendelian randomization methods.
- Key findings include protective microbes like Akkermansia muciniphila associated with ischaemic heart disease in certain ethnicities and a significant inverse relationship between blood lipids and the abundance of a microbial cluster named CMR.
Background: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including and .
Objectives: To investigate the effects of genetic variants on risk and time to LID.